Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Assets AverageDebt RatioDebt to EquityEnterprise ValueEquity AverageEquity RatioInvested CapitalReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested Capital

Spyre Therapeutics (SYRE) Equity Average (2016 - 2025)

Historic Equity Average for Spyre Therapeutics (SYRE) over the last 10 years, with Q3 2025 value amounting to $455.4 million.

  • Spyre Therapeutics' Equity Average rose 2979.56% to $455.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $455.4 million, marking a year-over-year increase of 2979.56%. This contributed to the annual value of $350.9 million for FY2024, which is 19951.22% up from last year.
  • As of Q3 2025, Spyre Therapeutics' Equity Average stood at $455.4 million, which was up 2979.56% from $469.2 million recorded in Q2 2025.
  • Over the past 5 years, Spyre Therapeutics' Equity Average peaked at $500.2 million during Q1 2025, and registered a low of -$226.4 million during Q3 2023.
  • Its 5-year average for Equity Average is $161.3 million, with a median of $110.6 million in 2021.
  • Its Equity Average has fluctuated over the past 5 years, first plummeted by 39844.11% in 2023, then surged by 147685.14% in 2024.
  • Quarter analysis of 5 years shows Spyre Therapeutics' Equity Average stood at $93.0 million in 2021, then plummeted by 36.64% to $58.9 million in 2022, then tumbled by 152.08% to -$30.7 million in 2023, then skyrocketed by 1476.85% to $422.6 million in 2024, then increased by 7.77% to $455.4 million in 2025.
  • Its last three reported values are $455.4 million in Q3 2025, $469.2 million for Q2 2025, and $500.2 million during Q1 2025.